Overview

• Enanta fiscal Q4 revenue missed analyst expectations

• Net loss for fiscal Q4 narrows year-over-year, indicating improved financial performance

• Company maintains "strong" cash position, bolstered by October 2025 public offering

Outlook

• Enanta plans to file IND for EPS-3903 in the second half of 2026

• Company expects cash and revenue to fund operations into fiscal 2029

• Enanta to submit IND for EDP-978 in Q1 2026

Result Drivers

• ABBVIE SALES - Increase in quarterly revenue attributed to higher sales of AbbVie's MAVYRET®/MAVIRET®

• REDUCED R&D EXPENSES- Research and development expenses were $23.8 million for the three months ended September 30, 2025, compared to $30.8 million for the three months ended September 30, 2024

• REDUCED G&A EXPENSES- General and administrative expenses totaled $9.7 million for the three months ended September 30, 2025, compared to $13.7 million for the three months ended September 30, 2024.

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 39.7% above its November 14 closing price of $12.06

Press Release: ID:nBwqQ3yLa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)